Efgartigimod Alfa

DRUG3 trials

Sponsors

Janssen Cilag International, Shanghai Zhongshan Hospital, Anastasia Vishnevetsky, MD, MPH

Conditions

Myasthenia GravisOptic Neuritisgeneralized myasthenia gravis

Phase 2

Perioperative Efgartigimod for Thymoma and Myasthenia Gravis

Not yet recruitingNCT06221501

Shanghai Zhongshan HospitalMyasthenia Gravis

Start: 2024-02-01End: 2027-06-30Target: 30Updated: 2024-01-24

Efgartigimod for the Treatment of Acute Optic Neuritis

RecruitingNCT06453694

Anastasia Vishnevetsky, MD, MPHOptic Neuritis

Start: 2025-08-12End: 2027-07-31Target: 20Updated: 2025-11-07

Phase 3

Efficacy and Safety of Nipocalimab vs Efgartigimod in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab

Not yet recruitingCTIS2025-521130-28-00

Janssen Cilag Internationalgeneralized myasthenia gravis

Target: 29Updated: 2025-12-14

Related Papers

Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial.

2025-05-025 citations